The present invention relates to preparations and methods fortreating a GD2 positive cancer by administering a preparationcomprising an anti-GD2 antibody to a patient, wherein the patient isnot concomitantly treated with Interleukin-2 (IL-2), and wherein oneor more treatment periods with the antibody is/are preceded,accompanied, and/or followed by one or more treatment periods with aretinoid. Furthermore, the invention relates to preparations andmethods for the treatment of a GD2 positive cancer in a patient,wherein a preparation comprising an anti-GD2 antibody isadministered to the patient as a continuous infusion for one or moredays and for two or more treatment cycles, without concomitantlyadministering IL-2. The present invention further relates topreparations and methods for the treatment of a GD2 positive cancerin a patient, wherein a preparation comprising an anti-GD2 antibodyis administered to the patient as a continuous infusion withoutconcomitantly administering IL-2, and wherein the anti-GD2 antibodyis not a 14G2a antibody.
